Is ablation to atrial fibrillation termination of persistent atrial fibrillation the end point?

A systematic review and meta-analysis

Fanghui Li, MD,a Xiang Tu, MD,b Dongze Li, MBBS,c,d, Ying Jiang, MDa, Yisong Cheng, MDd, Yu Jia, MDc,d, Xinyu Zhang, MDa, Hua Fu, MD, PhDf, Hongde Hu, MD, PhDg, Jian Jiang, MD, PhDg, Rui Zeng, MD, PhDh

Abstract

Background: The ideal ablation strategy and end point for persistent atrial fibrillation (AF) have not been well founded. Defining periprocedural AF termination as the end point of catheter ablation is still controversial. This meta-analysis aimed to analyze the differences between periprocedural AF termination and non-termination in the long-term AF recurrence rate and postoperative complications.

Methods: Randomized controlled trials (RCTs) were identified by a systematic search of electronic databases including PubMed, EMBASE, and Cochrane library from January 2008 to August 2019. The primary outcome was freedom from AF or any atrial arrhythmia without antiarrhythmic drugs at the long-term (≥12 months) follow-up. The secondary outcome was overall postoperative complication rates. The risk ratio (RR) with 95% confidence interval (CI) was pooled for these outcomes. A forest plot, fixed-effects model or random-effect model, Q-test, I-squared statistic, and Egger funnel plot were used in the statistical analysis.

Results: Fourteen RCTs were included in this meta-analysis. Overall, no significant difference was found in freedom from AF at the long-term follow-up between patients in whom AF termination was achieved and not achieved (RR = 1.11, 95% CI = 0.93-1.31, P = .14). Patients with AF non-termination had a lower complication occurrence rate than those with AF termination (RR = 0.78, 95% CI = 0.69-0.89, P = 0.00). A meta-regression analysis showed that the differences were evident in periprocedural AF termination.

Conclusion: Our meta-analysis suggests that AF termination is not a reliable procedural end point during ablation of persistent AF.

Keywords: persistent atrial fibrillation, radiofrequency ablation, atrial fibrillation termination, meta-analysis

1. Introduction

Atrial fibrillation (AF) is the most common arrhythmia encountered in the clinical setting, and it affects 2% of the general population.[1] It usually starts as brief periods of abnormal heart beating that become longer and persistent, but episodes often manifest with no symptoms.[2] Elderly people are the susceptible population of AF. The mortality and risk of stroke are increased largely for patients with AF. Thus far, substantial research has been done on the mechanism of AF, but it is still unclear.[3] Numerous studies have concluded that the occurrence of AF does not involve a single mechanism.[4-7] In some patients with AF, especially paroxysmal AF, pulmonary veins and other ectopic excitatory lesions can cause AF.[8] For persistent AF, the mechanism is much more complicated.

Catheter ablation is a procedure commonly used in symptomatic patients with drug-refractory AF to control symptoms. Pulmonary vein isolation is now widely used in paroxysmal AF, which is confirmed effective. Regarding persistent AF, it is much more difficult to terminate the arrhythmia during the procedure, and various strategies are used in centers. The optimal ablation strategy and end point for persistent AF have not been well established.[9] The preferred additional ablation targets and procedural end points are diverse, usually depending on the operator’s discretion.
Certain studies demonstrated that achieving AF termination is the best procedural end point during ablation for patients with persistent AF, and they claimed that it is more likely to maintain sinus rhythm (SR) in the long term. Nevertheless, ablation to AF termination means that the procedural duration is longer and repeat ablation rate is higher, although the perioperative risk and complications rates are unknown. In addition, some of those studies did not have consistent reproducibility. Several recent studies indicated that ablation for AF termination as a procedural end point lacks sufficient experimental, mechanistic, or clinical support and thus should not be the optimal end point.

As single studies may lack adequate evidence to provide reliable and comprehensive conclusions, a meta-analysis of all eligible studies should be performed. Therefore, in this meta-analysis, we analyzed the differences between periprocedural AF termination rate and postoperative complications and provided quantitative evidence to confirm whether AF termination is an appropriate and reliable procedural end point.

2. Material and methods

This systematic review and meta-analysis was conducted in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. This is a systematic review and ethical approval was not necessary.

2.1. Data sources and search strategy

Randomized controlled trials (RCTs) were identified by a systematic search of electronic databases including MEDLINE (PubMed), EMBASE, Cochrane Central from January 2008 to August 2019. The terms “atrial fibrillation,” and “radiofrequency ablation” were used to search titles, abstracts, and key words (See Information, Supplementary Content, which shows the search strategy details). The search was conducted by two independent researchers (FL and XT). Besides, for fear of losing additional relevant studies, we conducted a manual search of additional articles using references from relevant articles and review papers.

2.2. Study selection

Criteria for inclusion were as follows:

1. studies about patients with persistent AF receiving radiofrequency catheter ablation;
2. studies that included periprocedural termination and non-termination of AF during the index procedure; and
3. studies that assessed long-term freedom from AF or any atrial arrhythmia without antiarrhythmic drugs at the ≥12-month follow-up.

AF termination was defined as conversion to SR or atrial tachycardia (AT)/atrial flutter (AFL). Studies were excluded if the study was published as a review, case report, or an animal study and if the outcome of catheter ablation was not adjudicated as a major (primary or secondary) end point. There was no restriction for age, sex, and country of the studies. Two independent reviewers were responsible for identifying the studies (FL and DL).

2.3. Primary and secondary outcomes

The primary outcome was freedom from AF or any atrial arrhythmia without antiarrhythmic drugs at the long-term (≥12 months) follow-up. The secondary outcome was overall postoperative complication rates.

2.4. Data extraction

Data were extracted and quality assessments were performed independently by 2 main reviewers (XT and YJ). The following information was received from each eligible study: first author’s name, sample size, country of the study, year of publication, participants’ characteristics, duration of follow-up, adopted ablation strategy, left atrium (LA) diameter, AF termination rates, AF termination type, and long-term success rates for patients in whom periprocedural AF termination was achieved and those in whom the end point was not achieved.

2.5. Quality assessment

A quality assessment of each selected study was conducted by two investigators (FL and DL). We used the Cochrane Collaboration recommending tool to evaluate the risk of bias, with a focus on selection bias, detection bias, performance bias, attrition bias, and reporting bias. Any disagreements in the abstracted data were adjudicated by a third reviewer (YC).

2.6. Statistical analysis

The freedom from AF or any atrial arrhythmia without antiarrhythmic drugs at the ≥12-month follow-up (primary outcomes) and overall postoperative complication rates (secondary outcomes) are dichotomous variables. Hence, the risk ratio (RR) with 95% confidence interval (CI) was calculated for these primary and secondary outcomes. A forest plot for RCTs was constructed to assess the differences between periprocedural AF termination and non-termination in the AF recurrence rate and postoperative complication rate. The summary estimates were generated using a fixed-effects model (low heterogeneity) or a random-effects model (high heterogeneity). Statistical heterogeneity was assessed with the Q-test and I² statistic. I² values indicated the following: 25%, low heterogeneity; 50%, moderate heterogeneity; and 75%, high heterogeneity. When \( P > .1 \) and \( I^2 < 50\% \), the fixed-effects model was used; otherwise, the random-effects model was used. Sensitivity analysis was performed to investigate the effect of one study on the overall risk estimate by sequentially omitting a single study at a time. Potential publication bias was determined using Egger funnel plot. \( P < .05 \) was considered significant.

Additionally, in order to investigate whether the type of AF termination affected this study’s results, we divided the RCTs into the SR subgroup and SR atrial tachycardia/atrial flutter (SR AT/AFL) subgroup. Ablation techniques were different, as some studies used the same ablation strategy in the AF termination group and non-termination group; however, some used different strategies between the 2 groups. Therefore, we categorized the RCTs into the same ablation strategy (SAS) subgroup and different ablation strategy (DAS) subgroup. AF recurrence was defined differently. If the definition of AF recurrence was any episode of documented AF, it was assigned to the AF subgroup; otherwise, it was assigned to the AFAT/AFL subgroup. Apart from that, patients’ average LA diameter of included studies varied. If the patients’ average LA diameter of the study was more than 45 mm, it was assigned to the ≥45 mm subgroup; otherwise, it was assigned to the <45 mm subgroup. The Cochrane
Collaboration’s Review Manager software package (RevMan 5.3) was used for this meta-analysis.

3. Results

3.1. Search results

We identified 818 articles in the systematic literature search. One hundred and 96 studies were removed due to duplicated publication and 566 articles were excluded based on the titles or abstracts. We considered 56 articles and assessed their eligibility by reviewing the full text. Ultimately, 14 RCTs met the prespecified inclusion criteria and were included in this meta-analysis.[11,18–23,24–30] A study inclusion flow chart is shown in Figure 1.

3.2. Study characteristics

Detailed characteristics of all the included studies are presented in Table 1. All the included studies were published in the last 11 years between 2008 and 2019. Studies were conducted in centers across Europe, North America, Asia, Russia, and Australia, and they included 2212 participants. The age range of all participants was middle-aged and elderly, and the participants represented the population at high risk of having AF as well. The reported follow-up duration ranged from 10 to 42 months. All procedures were conducted using radiofrequency ablation. These studies used ablation strategies that were highly variable and included the following: only complex fractionated atrial electrogram (CFAE) ablation,[24] a combination of pulmonary vein antrum isolation plus CFAE with or without linear ablation,[11,18,19,22,23,24–29] and others.[20,21] Moreover, in certain studies, different strategies were used in the AF termination and non-termination groups. In these studies, freedom from AF was defined as no AF recurrence and no AF/AT/AFL recurrence. Table 1 shows a detailed description.

3.3. Study quality assessment

According to the Cochrane Collaboration recommending tool. The majority of studies had a low or unclear risk of bias, although 2 of those studies[20–25] did not have blinded participants and personnel, and 1 study[23] had a high risk of attrition bias. Results from the risk of bias assessment are shown in Figure 2.

3.4. Freedom from AF at long-term follow-up

Freedom from AF at the long-term follow-up was evaluated in 14 RCTs (n=2212). In these studies, periprocedural AF termination was achieved in 938 (42.4%) patients and not achieved in 1274 (57.6%) patients. Generally, no significant difference was found in freedom from AF at the long-term follow-up between patients in whom AF termination was achieved and not achieved. The AF recurrence rate after achieving AF termination was 0.93 times lower than after not achieving AF termination, it did not reach significance (RR = 0.93, 95% CI: 0.78-1.09, P=.36, I²=69%) (Fig. 3). Sensitivity analysis was performed by sequentially omitting one study at a time. There was no substantial change in the overall combined RRs, which ranged from 0.89 (95% CI: 0.76-1.05) to 0.97 (95% CI: 0.83-1.13) after excluding studies sequentially. Additionally, we found similar heterogeneity after each exclusion, and the I² values ranged from 62% to 71%. The results indicated that no single study dominated the combined RRs and heterogeneity. Egger test suggested that there was no publication bias, as presented in Fig. 4 (P=.360).

Figure 1. PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) flow diagram for study identification and inclusion.
### 3.5. Postoperative complications

In 9 studies, complications associated with periprocedural termination and non-termination of AF were reported (Table 2). Patients without AF termination had a lower complication rate than those with AF termination (RR = 1.74, CI = 1.11-2.73, P = 0.02, I² = 0%) (Fig. 5).

### Table 1

| Study ID (y) | Country | sample size | Gender (M/F) | Mean age ± standard deviation | Follow-up time (months) | Ablation technique | % of AF Termination | Type of AF Termination | Definition of AF Recurrence | LA diameter (mm) |
|--------------|---------|-------------|--------------|-----------------------------|--------------------------|--------------------|---------------------|-----------------------|---------------------------|-----------------|
| Ammar-Busch 2017 | Germany | 90 | 71/19 | 64 ± 9 | 12 | PVI + CFAE vs PVI + CFAE + Linear | 16 | SR | AEoD AF or AT/AFL > 30s | 48 ± 7 |
| Elayi 2008 | France | 144 | 95/49 | 59.1 ± 10.7 | 16 | PVI vs PVI + Linear vs PVI + CFAE | 44 | SR, AT/AFL | AEoD AF or AT/AFL > 30s | 45.4 ± 6.7 |
| Fink 2017 | Germany | 118 | 84/34 | 61.5 ± 9.7 | 12 | PVI vs PVI + Substrate Modification | 60 | SR | AEoD AF or AT/AFL > 30s | 47.0 ± 4.4 |
| Kim 2015 | Korea | 120 | 87/33 | 57.2 ± 10.8 | 12 | PVI + Linear vs PVI + Linear + PM | 78 | SR | AEoD AF or AT/AFL > 30s | 42.2 ± 5.8 |
| Kim 2017 | Korea | 137 | 98/39 | 61.6 ± 10.9 | 22.3 ± 13.2 | PVI + Linear vs CPVI + Linear + CFAE | 21.2 | SR | AEoD AF or AT > 30s | 45.0 ± 5.46 |
| Kochhäuser 2017 | Canada | 549 | - | - | - | - | - | - | - | - |
| Lin 2014 | China | 90 | 74/12 | 52 ± 11 | 15 ± 11 | PVI + CFAE | 25 | SR | AEoD AF or AT/AFL > 30s | 44.9 ± 16.16 |
| Oral 2008 | USA | 85 | 74/11 | 59 ± 10 | 17 ± 6 | CFAE | 24 | SR, AT/AFL | AEoD AF | 46.5 ± 6.49 |
| Oral 2009 | USA | 119 | 96/23 | 60 ± 9 | 12 | PVI + CFAE vs PVI | 24 | SR, AT/AFL | AEoD AF | 46.5 ± 5.99 |
| Rostock 2013 | Germany | 110 | 88/22 | 63 ± 9 | 20.1 ± 13.3 | PVI vs PVI + Electrogram-based ablation | 33 | SR | AEoD AF or AT/AFL > 30s | 45.5 ± 6.50 |
| Wang YL 2017 | China | 96 | 45/51 | 59.9 ± 9.5 | 12 | PVI + CFAE | 65.7 | SR | AEoD AF or AT/AFL | 45.5 ± 4.01 |
| Wang YL 2015 | UK | 130 | 98/32 | 58 ± 10 | 42 | PVI + Linear + CFAE | 44.7 | SR, AT/AFL | AEoD AF > 30s | 46.6 ± 5.95 |
| Wong 2015 | UK | 130 | 88/42 | 61 ± 10.5 | 12 | PVI + Linear vs PVI + CFAE | 26 | SR | AEoD AF or AT/AFL | 46 ± 6 |
| Wong 2016 | UK | 130 | 98/32 | 61 ± 10.5 | 35 ± 5 | PVI vs PVI + Linear + CFAE | 72 | SR | AEoD AF or AT/AFL > 30s | 43 ± 6 |

**AEoD** = any episode of documented; **AF** = atrial fibrillation; **AT/AFL** = intermediate atrial tachycardia/flutter; **CFAE** = complex fractionated atrial electrograms; **LA** = left atrium; **PVI** = pulmonary vein isolation; **PM** = posterior wall isolation; **SR** = sinus rhythm; **UK** = United Kingdom; **USA** = the United States of America.
| Study or Subgroup | AF termination | AF non-termination | Risk Ratio M-H, Random, 95% CI | M-H, Random, 95% CI |
|------------------|----------------|-------------------|------------------------------|--------------------|
| Ammar-Busch 2017 | 38 events 45 total 28 events 45 | 9.0% 1.36 (1.05, 1.76) | 1.06 (0.86, 1.32) |
| Elayi 2008       | 19 events 49 total 71 events 95 | 73% 0.52 (0.36, 0.75) | 0.59 (0.42, 0.82) |
| Fink 2017        | 36 events 54 total 35 events 59 | 8.6% 1.12 (0.85, 1.49) | 1.19 (0.86, 1.64) |
| Kim 2015         | 10 events 60 total 22 events 60 | 4.1% 0.45 (0.24, 0.88) | 0.63 (0.34, 1.15) |
| Kim 2017         | 17 events 54 total 10 events 54 | 3.9% 1.70 (0.86, 3.37) | 2.00 (1.04, 3.86) |
| Kochhause 2017   | 68 events 143 total 235 events 406 | 10% 0.82 (0.68, 0.99) | 1.04 (0.82, 1.32) |
| Lin 2014         | 15 events 41 total 23 events 45 | 5.7% 0.72 (0.44, 1.17) | 0.74 (0.43, 1.29) |
| Oral 2008        | 25 events 33 total 21 events 33 | 8.0% 1.19 (0.86, 1.64) | 1.12 (0.82, 1.55) |
| Oral 2009        | 32 events 50 total 31 events 50 | 8.4% 1.03 (0.76, 1.39) | 0.93 (0.66, 1.36) |
| Rostock 2013     | 25 events 55 total 37 events 55 | 7.7% 0.68 (0.48, 0.95) | 0.74 (0.50, 1.10) |
| Wang 2017        | 8 events 27 total 21 events 48 | 4.0% 0.68 (0.35, 1.32) | 0.69 (0.42, 1.12) |
| Wang YL 2017     | 91 events 159 total 106 events 168 | 9.9% 0.85 (0.70, 1.04) | 0.91 (0.67, 1.24) |
| Wong 2015        | 35 events 65 total 28 events 65 | 7.5% 1.25 (0.87, 1.79) | 1.06 (0.70, 1.61) |
| Wynn 2016        | 24 events 63 total 19 events 61 | 5.8% 1.22 (0.75, 1.99) | 1.12 (0.64, 1.94) |
| Total (95% CI)   | 938 events 244 total 1274 events 100% | 0.93 (0.78, 1.09) | 1.04 (0.82, 1.33) |

Figure 3. Forest plot demonstrating the differences of postoperative complication recurrence rates between periprocedural AF termination and non-termination.

Figure 4. Risk of bias of included studies in the meta-analysis.

Table 2

| Study                  | AF termination | AF non-termination |
|------------------------|----------------|--------------------|
|                        | Complication   | Number of patients (n = 938) | Complication   | Number of patients (n = 1274) |
| Fink [23] (2017)       | Cardiac tamponade | 2 | Stroke               | 1 |
|                        | Stroke         | 1 | Transient ischemic attack | 1 |
|                        | Groin bleeding requiring transfusion | 2 | Groin bleeding requiring transfusion | 1 |
|                        | Groin bleeding requiring surgical therapy | 2 | |
| Oral [24] (2008)       | -              | 0 | Pericarditis          | 1 |
| Wang [27] (2017)       | Minor bleeding | 5 | Minor bleeding        | 7 |
| Wynn [26] (2016)       | Unclear        | 6 | Unclear               | 5 |
| Elayi [19] (2008)      | Asymptomatic PV stenosis | 1 | Asymptomatic PV stenosis | 1 |
|                        | Pericardial effusions | 2 | |
| Wong [29] (2015)       | Cardiac tamponade | 11 | Atrial-esophageal fistulas | 1 |
| Wang YL [28] (2017)    | Cardiac tamponade | 3 | Cardiac tamponade     | 1 |
|                        | Femoral hematomas | 8 | Femoral hematomas    | 5 |
|                        | Reversible right phrenic nerve injuries | 3 | |
| Ammar-Busch [18] (2017) | Pseudoaneurysm | 2 | LAA isolation | 1 |
|                        | Asymptomatic PV stenosis | 1 | Pericarditis | 1 |
|                        | Unclear        | 4 | Unclear               | 3 |
| Total patients         |                | 44 |                         | 29 |

AF = atrial fibrillation; LAA = left atrial appendage; PV = pulmonary vein.
Otherwise, the types of complications were more variable and severe in AF termination compared with AF non-termination. We performed sensitivity analysis by sequentially omitting one study at a time. However, $I^2$ and RR were not significantly different, which indicates that our results were robust. Egger test result suggested no publication bias, as presented in Fig. 4 ($P = .408$). Because the study sample of patients with postoperative complications was relatively small, further analysis was not done.

### 3.6. Subgroup analysis

Nine RCTs defining AF termination as achieving SR were classified in the SR subgroup. The other 5 RCTs defining AF termination as achieving SR or AT/AFL were categorized as the SR AT/AFL subgroup. The SR and SR AT/AFL subgroups showed no difference in freedom from AF at the long-term follow-up between patients in whom AF termination was achieved and not achieved. (SR subgroup: RR = 0.97, 95% CI = 0.76-1.24, $P = .83, I^2 = 67$%; SR AT/AFL subgroup: RR = 0.86, 95% CI = 0.70-1.06, $P = .16, I^2 = 69$%) (Table 3).

Three studies used the same ablation strategy between the AF termination group and non-termination group, whereas 11 studies used different ablation strategies between the groups. The 2 subgroups showed no significant difference between patients with and without periprocedural AF termination (SAS subgroup: RR = 0.92, 95% CI = 0.71-1.20, $P = .54, I^2 = 52$%; DAS subgroup: RR = 0.93, 95% CI = 0.75-1.14, $P = .47, I^2 = 74$%) (Table 3).

There were ten studies divided into the $\geq 45$ mm subgroup and four studies divided into the $< 45$ mm subgroup. Both of the subgroups claimed that there was no significant difference between patients with and without periprocedural AF termination ($\geq 45$ mm subgroup: RR = 0.98, 95% CI = 0.80-1.19, $P = .81, I^2 = 72$%; $< 45$ mm subgroup: RR = 0.80, 95% CI = 0.59-1.07, $P = .14, I^2 = 50$%) (Table 3).

Ten studies were classified in AF/AT/AFL subgroup, and four studies were classified in AF subgroup. The 2 subgroups showed no significant difference between patients with and without periprocedural AF termination (AF/AT/AFL subgroup: RR = 0.90, 95% CI = 0.69-1.18, $P = .44, I^2 = 76$%; AF subgroup: RR = 0.93, 95% CI = 0.79-1.08, $P = .33, I^2 = 40$%) (Table 3).

To sum up, type of AF termination, ablation techniques used for AF patients, LA diameter and definition of AF recurrence all had no effect on the results.

### 4. Discussion

This meta-analysis of studies from the past 11 years on ablation for persistent AF patients clarified that there is no statistical difference between periprocedural AF termination and non-

---

**Table 3**

| Factors | No. | RR (95% CI) | $P$ | $I^2$ | Heterogeneity, $P$ |
|---------|-----|-------------|-----|------|-------------------|
| Type of AF termination | | | | | |
| SR | 9 | 0.97 (0.76-1.24) | .830 | 67 | .002 |
| SR AT/AFL | 5 | 0.86 (0.70-1.06) | .160 | 69 | .100 |
| Ablation strategy | | | | | |
| SAS | 3 | 0.92 (0.71-1.20) | .540 | 52 | .130 |
| DAS | 11 | 0.93 (0.75-1.14) | .470 | 74 | <.0001 |
| LA diameter | | | | | |
| $\geq 45$ mm | 10 | 0.98 (0.80-1.19) | .810 | 72 | .0002 |
| $< 45$ mm | 4 | 0.80 (0.59-1.07) | .140 | 50 | .110 |
| Definition of AF recurrence | | | | | |
| AF | 4 | 0.93 (0.79-1.08) | .330 | 40 | .17 |
| AF/AT/AFL | 10 | 0.90 (0.69-1.16) | .440 | 76 | <.0001 |

AF = atrial fibrillation; AT/AFL = intermediate atrial tachycardia/flutter; CI = confidence interval; DAS = different ablation strategy; LA = left atrium; RR = risk ratio; SAS = same ablation strategy; SR = sinus rhythm.
termination in AF recurrence. The subgroup analysis showed that type of AF termination, ablation techniques used for AF patients, LA diameter and definition of AF recurrence all had no effect on the results. Statistically, periprocedural AF termination cannot be used as an individual predictor of the long-term prognosis of patients with AF.

Recently, the choice of using AF periprocedural ablation as the end point has been a controversial discussion in the field of arrhythmia and an urgent problem to be solved. Many studies have analyzed the merits and defects of different strategies. In 2012, Shah et al. [31] summarized acute termination, postablation arrhythmia, and extended clinical success depending on the perioperative strategies in 19 studies, and they recommended AF termination as the end point. However, in the same year, Santangelo [12] published a systematic review article claiming that AF termination should not be the end point. Regardless of its controversy, many new research studies have been published about AF termination. We included the latest studies published over the last 10 years and performed a meta-analysis with the aim of obtaining a robust conclusion.

Once the mechanism of a disease is discovered, the disease be treated more properly using the best strategy. However, to date, the mechanisms of AF remain unclear. [2,3] Epigenetic regulators may play a role in AF genesis and microRNAs was used as AF fibrotic and electrical alterations biomarkers. [32] And some other comorbidities such as diabetes and chronic obstructive pulmonary disease (COPD) may be relevant triggers and aggravating factors for AF pathogenesis and recurrence. [3,34] In persistent and long-standing AF, triggers and drivers vary remarkably among patients. The most important treatment for paroxysmal and persistent AF is catheter ablation, which can achieve procedural AF termination and conversion to SR. With regard to long-term treatment outcomes, recurrence and complications should be considered. Stroke is one of the major complications of AF. In high-risk patient populations, subclinical AF recurrence were associated with a significantly increased risk of stroke. [35] It has been confirmed that the pathogenesis of AF is usually progressive, and the mechanisms are changeable even in the same patient. [36–38] Therefore, even if ablation achieves procedural AF termination and conversion to SR, it cannot prevent AF from developing other new mechanisms with subsequent clinical recurrences. It is common for patients with persistent AF to be admitted to a hospital because of AF recurrence. One study showed that 0.3%/year of patients with paroxysmal AF are likely to be diagnosed with persistent AF years after catheter ablation. [39] We can learn from these clinical facts because they highlight the fact that acute conversion to SR is not significant and essential for the long-term prognosis of patients with persistent AF.

There was no significant statistical difference between periprocedural AF termination and non-termination of persistent AF in long-term AF recurrence; however, complication rates were higher in patients with AF termination than in those without AF termination. Usually, more ablation will be performed in order to achieve procedural AF termination. [39] When the procedural time is prolonged, it is likely to increase the risk of complications, such as cardiac tamponade, pericarditis, atrioesophageal fistula, fluid overload, and anesthetic complications. [1,7] According to the present study, AF termination is not the best strategy for patients with persistent AF. In clinical practice, all prognostic factors including the procedural duration, patients’ health status, and ablation strategy should be considered. Sardu’s study [32] demonstrated that epigenetic-assisted radiofrequency ablation with microRNA target therapy may reduce recurrence of atrial fibrillation after ablation. Another study [40] showed that an oral antioxidant treatment (α-lipoic acid) reduced ablated patients’ serum levels of common markers of inflammation which may relate to AF pathogenesis and recurrence. Moreover, monitoring devices could early detect AF and avoid AF recurrences and hospital admissions for AF. [41] It is excellent if AF terminates and converts to SR after the first ablation. However, if not, the procedure does not have to be prolonged. Drugs and other medical strategies can help with the conversion and recovery. More clinical trials are needed to support our view on the ablation end point of persistent AF.

5. Limitations

There are some limitations to this study. First, the eligible studies were limited; therefore, it is difficult to examine heterogeneity of the studies. Second, certain studies without adjustment for confounders were excluded from the meta-analysis, which may account for the introduction of bias. Third, only a few studies mentioned postoperative complications; thus, more data are needed to analyze the association between complications and perioperative strategies.

6. Conclusions

The results of this meta-analysis showed no significant difference between periprocedural AF termination and non-termination of persistent AF in the long-term AF recurrence rate. Patients with AF non-termination had a lower complication rate than those without AF termination. AF termination is not an optimal and reliable procedural end point during ablation of persistent AF. Operators should select the AF ablation strategy according to patient-specific characteristics and preferences in addition to operators’ experience and preference.

Author Contribution

Rui Zeng and Dongze Li contributed to the conception of the study; Ying Jiang, Yisong Cheng, Yu Jia and Xinyu Zhang contributed significantly to analysis and manuscript preparation; Fanghui Li and Xiang Tu performed the data analyses and wrote the manuscript; Hua Fu, Hongde Hu, Jian Jiang helped perform the analysis with constructive discussions.

References

[1] Carter L, Gardner M, Magee K, et al. An integrated management approach to atrial fibrillation. J Am Heart Assoc Jan 2016;25:3.
[2] Andrade J, Khary P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res Apr 2014;114:1453–68.
[3] Nishida K, Datino T, Macle L, et al. Atrial fibrillation ablation: translating basic mechanistic insights to the patient. J Am Coll Cardiol Aug 2014;64:823–31.
[4] Goudis CAKE, Vardas PE. Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation. Europace 2012;14:623–30.
[5] JCWLA JS. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:e199.
[6] Pellman JLR, Sheikh F. Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation. J Mol Cell Cardiol 2010;48:1e467.

[7] Tan HCK, Chen F, Yao Y, et al. Trypsate promotes the profibrotic phenotype transfer of atrial fibroblasts by PAR2 and PARy pathway. Arch Med Res 2018;12:1–8.

[8] LJHCB MW. Ectopic activity induced by elevated atrial pressure in rabbit pulmonary vein in vitro. Chin Med J (Engl) 2005;118:1210.

[9] Latchamsetty R, Oral H. Is ablation to termination the best strategy for ablation of persistent atrial fibrillation? Ablation to termination is not the best strategy during ablation. Circ Arrhythm Electrophysiol Aug 2015;8:972–80.

[10] Scherr D, Khairy P, Miyazaki S, et al. Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol Feb 2015;8:18–24.

[11] Lin YJ, Chang SL, Lo LW, et al. A prospective and randomized comparison of limited versus extensive atrial substrate modification after circumferential pulmonary vein isolation in nonparoxysmal atrial fibrillation. J Cardiovasc Electrophysiol Aug 2014;25:603–12.

[12] Santangeli P, Di Biase L, Al-Ahmad A, et al. Ablation for atrial fibrillation: termination of atrial fibrillation is not the end point. Card Electrophysiol Clin Sep 2012;4:343–52.

[13] Moher D, Tetzlaff LA, Altman JDG. Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.

[14] Higgins GGS. Cochrane handbook for systematic reviews of interventions version 5.1.0. Updated March. London: The Cochrane Collaboration; 2011. 2011.

[15] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med Oct 18 2011;155:329–36.

[16] Der Simonian RLN. Meta-analysis in clinical trials. Control Clin Trials 1986;7:477.

[17] WG C. The combination of estimates from different experiments. Biometrics 1954;10:101–29.

[18] Ammar-Busch S, Bourier F, Reents T, et al. Ablation of complex fractionated electrograms with or without Additional LINear Lesions for Persistent Atrial Fibrillation (The ALINE Trial). J Cardiovasc Electrophysiol Jun 2017;28:636–41.

[19] Elayi CS, Verma A, Di Biase L, et al. Ablation for longstanding permanent atrial fibrillation: results from a randomized study comparing three different strategies. Heart Rhythm Dec 2006;3:1658–64.

[20] Fink T, Schluter M, Heeger GH, et al. Stand-alone pulmonary vein isolation versus pulmonary vein isolation with additional substrate modification as index ablation procedures in patients with persistent and long-standing persistent atrial fibrillation: the randomized aIter-lost-AF Trial (Ablation at St. George Hospital for Long-Lasting Persistent Atrial Fibrillation), Circ Arrhythm Electrophysiol Jul 2017;10.

[21] Kim JS, Shin SY, Na JO, et al. Does isolation of the left atrial posterior wall improve clinical outcomes after radiofrequency catheter ablation for persistent atrial fibrillation: A prospective randomized clinical trial. J Interven Cardiol Feb 2015;28:65–71.

[22] Kim TH, Uhm JS, Kim JY, et al. Does additional electrogram guided ablation after linear ablation reduce recurrence after catheter ablation for longstanding persistent atrial fibrillation?: A prospective randomized study. J Am Heart Assoc Feb 2017;7:6.

[23] Kochhauser S, Jiang CY, Betts TR, et al. Impact of acute atrial fibrillation termination and prolongation of atrial fibrillation cycle length on the outcome of ablation of persistent atrial fibrillation: A substudy of the STAR AF II trial. Heart Rhythm Apr 2017;14:476–83.

[24] Oral H, Chugh A, Good E, et al. Randomized evaluation of right atrial ablation after left atrial ablation of complex fractionated atrial electrograms for long-lasting persistent atrial fibrillation. Circ Arrhythm Electrophysiol Apr 2008;1:16–13.

[25] Oral H, Chugh A, Yoshida K, et al. A randomized assessment of the incremental role of ablation of complex fractionated atrial electrograms after atrial pulmonary vein isolation for long-lasting persistent atrial fibrillation. J Am Coll Cardiol Mar 2009;53:782–9.

[26] Rostock T, Salukhe TV, Hoffmann BA, et al. Prognostic role of subsequent atrial tachycardias occurring during ablation of persistent atrial fibrillation: a prospective randomized trial. Circ Arrhythm Electrophysiol Dec 2013;6:1039–65.

[27] Wang M, Zhao Q, Ding W, et al. Comparison of direct current synchronized cardioversion to dcsh shock-guided catheter ablation for long-term sinus rhythm maintenance after isolated pulmonary vein isolation of persistent atrial fibrillation. Am J Cardiol Jun 15 2017;119:1997–2002.

[28] Wang YL, Liu X, Zhang Y, et al. Optimal endpoint for catheter ablation of longstanding persistent atrial fibrillation: a randomized clinical trial. Pacing Clin Electrophysiol Feb 2018;41:172–8.

[29] Wong KC, Paisley JR, Sopher M, et al. No benefit of complex fractionated atrial electrogram ablation in addition to circumferential pulmonary vein ablation and linear ablation: benefit of complex ablation study. Circ Arrhythm Electrophysiol Dec 2015;8:1316–24.

[30] Wynn GJ, Panikker S, Morgan M, et al. Biatrial linear ablation in patients with paroxysmal atrial fibrillation: the randomized alster-lost-AF catheter ablation to termination is not the end point. Card Electrophysiol Clin Sep 2012;4:335–42.

[31] Sardu C, Santamaría M, Paolillo G, et al. MicroRNA expression changes after atrial fibrillation catheter ablation. Pharmacogenomics Nov 2015;16:1863–77.

[32] Matsareaa A, Sardüh C, Shu J, et al. Why is chronic obstructive pulmonary disease linked to atrial fibrillation? A systematic overview of the underlying mechanisms. Int J Cardiol Feb 2019;276:149–51.

[33] Rizzo MR, Sasso FC, Marfella R, et al. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complications Sept 2015;29:88–92.

[34] Martella R, Sasso FC, Siniscalchi M, et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol Aug 2013;62:525–30.

[35] Baman TS, Gupta SK, Billakanty SR, et al. Time to cardioversion of recurrent atrial arrhythmias after catheter ablation of atrial fibrillation and long-term clinical outcome. J Cardiovasc Electrophysiol Dec 2009;20:1321–5.

[36] de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol Feb 2010;55:725–31.

[37] Jongnarangsin K, Suwannagool A, Chugh A, et al. Effect of catheter ablation on progression of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol Jan 2012;23:9–14.

[38] Takagawa M, Takahashi A, Kuwahara T, et al. Long-term follow-up after catheter ablation of paroxysmal atrial fibrillation: the incidence of recurrence and progression of atrial fibrillation. Circ Arrhythm Electrophysiol Apr 2014;7:267–73.

[39] Sardu Celestino, Santulli Gaetano, Santamaria Matteo, et al. Effects of α-Lipoic acid on multiple cytokines and biomarkers and recurrence of atrial fibrillation within one year of catheter ablation. Am J Cardiol May 2017;119:1382–6.